首页> 外文期刊>National Journal of Community Medicine >Adverse Drug Reactions and Outcome Analysis of MDR TB Patients on DOTS Plus Regimen
【24h】

Adverse Drug Reactions and Outcome Analysis of MDR TB Patients on DOTS Plus Regimen

机译:DOTS +方案对耐多药结核病患者的不良药物反应和结果分析

获取原文
       

摘要

"Introduction: The emergence of drug resistant mycobacteria has become a significant public health problem world over creating an obstacle to effective TB control. Present study was conducted to evaluate pattern and frequency of adverse drug reactions (ADR) of CAT IV, to analyze demographic, radiological and bacteriological profile and treatment outcome in MDR TB patients. Method: Total 102 MDR TB patients (with in vitro resistance to Isoniazid and Rifampicin) were analyzed retrospectively who had completed treatment from august 2007 to June 2014. Analysis was made for extent of lung lesion, correlation of sputum smear and culture conversion with clinical and radiological improvement, risk factors for adverse outcome and adverse drug reactions. Result: Forty six patients (45.09%) were cured/treatment completed, nine patients (8.82%) failed, 21 patients (20.05%) defaulted and 26 patients (25.49%) died of total 102 patients. Mean time for sputum smear and culture conversion were 4.2±2.0 and 4.19±2.3 months, respectively. Advanced lung lesion, cavitations, poor adherence to treatment and BMI less than 18 are variables associated with poor outcome. Fifty (52.94%) patients experienced adverse drug reactions and 42 of them required drug modifications. Conclusion: The ADRs were more common in the first 60 days of the regimen & in patient with BMI
机译:“简介:耐药性分枝杆菌的出现已成为一个重要的公共卫生问题,已经成为有效控制结核病的障碍。目前的研究旨在评估CAT IV的不良药物反应(ADR)的方式和频率,以分析人口统计学,方法:回顾性分析2007年8月至2014年6月完成治疗的102例耐多药结核病(对异烟肼和利福平具有体外耐药性)的耐多药结核病患者的放射学和细菌学特征以及治疗结果。病灶,痰涂片和培养转变与临床和影像学改善之间的相关性,不良结局和药物不良反应的危险因素结果:治愈/治疗的患者有46例(45.09%),失败的9例(8.82%),21例102例患者中有22.0%的患者违约,其中26例患者死亡(25.49%),痰涂片和培养转化的平均时间为4.2±2.0和4.19±2.3个月。晚期肺部病变,空化,对治疗的依从性差以及BMI小于18是与不良预后相关的变量。五十名患者(52.94%)出现药物不良反应,其中42名患者需要药物治疗。结论:ADR在方案的前60天和BMI患者中更为常见

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号